FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Cni Q1: Eps Beats, Revenue Lags, Operational Gains Amid Headwinds

作者

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

CNI posted Q1 adjusted EPS of CAD1.80, topping our CAD1.73 estimate but missing the consensus CAD1.81 forecast. Revenue declined 1% to CAD4.38B, as 3% volume growth was offset by a 3% freight revenue per RTM decline from FX and carbon tax headwinds. The operating ratio deteriorated 80 bps to 64.2%, as cost inflation outpaced revenue growth despite operational improvements including record Q1 fuel efficiency and 8% employee productivity gains. Segment performance was mixed: grain/fertilizers surged 10% while metals/minerals fell 11%, though underlying momentum remained solid with 2% constant currency revenue growth. Management reiterated expectations for flattish RTM growth in FY 26, with EPS growth slightly exceeding volume growth and a continued CAD2.8B capex program. FCF surged 44% to CAD900M, supporting CAD869M in share repurchases. We view the strong operational metrics and cash generation positively, though margin pressure from inflationary costs and FX headwinds remains a near-term concern.

相关文章

Australia

瑞银表示,星巴克将保持销售增长势头,下半年将重点关注利润率。

瑞银周三在一份报告中指出,星巴克 (SBUX) 有望在其转型战略的推动下保持强劲的销售势头,但投资者关注的焦点正转向下半年的利润率复苏。 瑞银表示,第二季度强劲的交易驱动型同店销售增长反映了运营改善、菜单创新和更新的会员计划。 展望未来,瑞银表示,持续推进下午饮品平台、会员计划升级、门店关闭和运营改进等举措应能支撑下半年的销售增长。 瑞银还预计,在销售杠杆、成本节约以及关税和咖啡成本压力缓解的推动下,星巴克的利润率将在今年晚些时候有所提升。 瑞银将星巴克的目标股价从100美元上调至105美元,但维持“中性”评级。Price: $106.10, Change: $+8.82, Percent Change: +9.06%

$SBUX
Australia

美国银行证券上调评级后,Elevance Health股价上涨

周三,Elevance Health (ELV) 股价上涨 2.5%,此前美国银行证券将该股评级从“中性”上调至“买入”,目标价为 435 美元。 成交量约为 140 万股,低于日均 190 万股以上。Price: $371.74, Change: $+9.00, Percent Change: +2.48%

$ELV
Australia

Wedbush将Biogen的目标股价从191美元上调至196美元,理由是“催化引擎正在加速运转”,并维持中性评级。

根据FactSet调查的分析师报告,百健(BIIB)的平均评级为“增持”,平均目标价为213.79美元。 (报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们:https://www..com/contact-us)Price: $195.08, Change: $+11.70, Percent Change: +6.38%

$BIIB